Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions

Neuropsychopharmacology

Volumn 42, Issue 1, 2017, Pages 299-317

  Miller, Brian J ^a   Goldsmith, David R ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; COMPLEMENT; CYTOKINE; METHOTREXATE; TOCILIZUMAB;

AUTOIMMUNE DISEASE; COMORBIDITY; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFECTION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRENATAL PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; FEMALE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE;

ANIMALS; BRAIN; FEMALE; HUMANS; INFLAMMATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; SCHIZOPHRENIA;

EID: 84991641369     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.211     Document Type: Review

References (217)

1. Abdeljaber MH, Nair MP, Schork MA, Schwartz SA (1994). Depressed natural killercell activity in schizophrenic patients. Immunol Invest 23: 259-268.
2. Ahokas A, Rimón R, Koskiniemi M, Vaheri A, Julkunen I, Sarna S (1987). Viralantibodies and interferon in acute psychiatric disorders. J Clin Psychiatry 48:194-196.
3. Ajami A, Abedian F, Hamzeh Hosseini S, Akbarian E, Alizadeh-Navaei R, Taghipour M(2014). Serum TNF-, IL-10 and IL-2 in schizophrenic patients before and aftertreatment with risperidone and clozapine. Iran J Immunol 11: 200-209.
4. Alexander KS, Pocivavsek A, Qu HQ, Pershing ML, Schwarcz R, Bruno JP (2013). Early developmental elevations in brain kynurenic acid impair cognitive flexibility inadults: reversal with galantamine. Neuroscience 238: 19-28.
5. Allswede DM, Buka SL, Yolken RH, Torrey EF, Cannon TD (2016). Elevated maternalcytokine levels at birth and risk for psychosis in adult offspring. Schizophr Res 50920-9964: 30077-30079.
6. Aoyama N, Takahashi N, Saito S, Maeno N, Ishihara R, Ji X, et al. (2006). Associationstudy between kynurenine 3-monooxygenase gene and schizophrenia in theJapanese population. Genes Brain Behav 5: 364-368.
7. Arakelyan A, Zakharyan R, Khoyetsyan A, Poghosyan D, Aroutiounian R, Mrazek Fet al (2011). Functional characterization of the complement receptor type 1 and itscirculating ligands in patients with schizophrenia. BMC Clin Pathol 11: 10.
8. Aguilar-Valles A, Flores C, Luheshi GN (2010). Prenatal inflammation-inducedhypoferremia alters dopamine function in the adult offspring in rat: relevance forschizophrenia. PLoS One 5: e10967.
9. Banati R, Hickie IB (2009). Therapeutic signposts: using biomarkers to guide bettertreatment of schizophrenia and other psychotic disorders. Med J Aust 190: S26.
10. Barry S, Clarke G, Scully P, Dinan TG (2009). Kynurenine pathway in psychosis:evidence of increased tryptophan degradation. J Psychopharmacol 23: 287-294.
11. Bauman MD, Iosif A, Smith SE, Bregere C, Amaral DG, Patterson PH (2014). Activation of the maternal immune system during pregnancy alters behavioraldevelopment of rhesus monkey offspring. Biol Psychiatry 75: 332-341.
12. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J (2008). CannabinoidCB2 receptors in human brain inflammation. Br J Pharmacol 153: 277-285.
13. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB(2011). Autoimmune diseases and severe infections as risk factors forschizophrenia: a 30-year population-based register study. Am J Psychiatry 168:1303-1310.
14. Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB(2014). A Nationwide study on the risk of autoimmune diseases in individuals witha personal or a family history of schizophrenia and related psychosis. Am JPsychiatry 171: 218-226.
15. Bilbo SD, Schwarz JM. (2009). Early-life programming of later-life brain andbehavior: a critical role for the immune system. Front Behav Neurosci 3: 14.
16. Bitanihirwe BK, Woo TU. (2011). Oxidative stress in schizophrenia: an integratedapproach. Neurosci Biobehav Rev 35: 878-893.
17. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. (2016). Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an[(11)c]pbr28 pet brain imaging study. Am J Psychiatry 173: 44-52.
18. Boyajyan A, Khoyetsyan A, Chavushyan A (2010). Alternative complement pathwayin schizophrenia. Neurochem Res 35: 894-898.
19. Børglum AD, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen CB, et al. (2014). Genome-wide study of association and interaction with maternalcytomegalovirus infection suggests new schizophrenia loci. Mol Psychiatry 19:325-333.
20. Brown AS, Derkits EJ (2010). Prenatal infection and schizophrenia: a review ofepidemiologic and translational studies. Am J Psychiatry 167: 261-280.
21. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al. (2004). Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161: 889-895.
22. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008). Peripheralinflammation is associated with altered substantia nigra activity and psychomotorslowing in humans. Biol Psychiatry 63: 1022-1029.
23. Buhimschi IA, Buhimschi CS, Weiner CP (2003). Protective effect of N-acetylcysteineagainst fetal death and preterm labor induced by maternal inflammation. Am JObstet Gynecol 1881: 203-208.
24. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH (2001). Maternal Cytokine Levels during Pregnancy and Adult Psychosis. Brain BehavImmun 15: 411-420.
25. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivy JR, Crowe RJ, et al. (2012). Dopaminergic mechanisms of reduced basal ganglia responses to hedonicreward during interferon alpha administration. Arch Gen Psychiatry 69:1044-1053.
26. Carrizo E, Fernández V, Quintero J, Connell L, Rodríguez Z, Mosquera M (2008). Coagulation and inflammation markers during atypical or typical antipsychotictreatment in schizophrenia patients and drug-free first-degree relatives. SchizophrRes 103: 83-93.
27. Chaudhry IB, Husain N, ur Rahman R, Husain MO, Hamirani MM, Kazmi A, et al. (2015). A randomised double-blind placebo-controlled 12-week feasibility trial ofmethotrexate added to treatment as usual in early schizophrenia: study protocolfor a randomised controlled trial. Trials 16: 9.
28. Chen AT, Chibnall JT, Nasrallah HA (2015). A meta-analysis of placebo-controlledtrials of omega-3 fatty acid augmentation in schizophrenia: possible stage-specificeffects. Ann Clin Psychiatry 27: 289-296.
29. Chen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Wu CS, et al. (2012). Prevalence ofautoimmune diseases in in-patients with schizophrenia: nationwide populationbasedstudy. Br J Psychiatry 200: 374-380.
30. Chen, da C, Qi LY, Xiu MH, Cao LY, Wang F, et al. (2008). Elevated serum levels oftumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia. Schizophr Res 106: 367-368.
31. Chiappelli J, Pocivavsek A, Nugent KL, Notarangelo FM, Kochunov P, Rowland LMet al (2014). Stress-induced increase in kynurenic acid as a potential biomarker forpatients with schizophrenia and distress intolerance. JAMA Psychiatry 71: 761-768.
32. Ching ASC, Kuhnast B, Damont A, Roeda D, Tavitian B, Dollé F (2012). Currentparadigm of the 18-kDa translocator protrain (TSPO) as a molecular target forPET imaging in neuroinflammation and neurodegenerative diseases. InsightsImaging 3: 111-119.
33. Choi GB, Kim YS, Wong H, Kim S, Kim H, Kim SV, et al. (2016). The maternalinterleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science 351: 933-939.
34. Clarke MC, Tanskanen A, Huttunen M, Whittaker JC, Cannon M (2009). Evidence foran interaction between familial liability and prenatal exposure to infection in thecausation of schizophrenia. Am J Psychiatry 166: 1025-1030.
35. Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, et al. (2015). Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry 173: 373-384.
36. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan K, Natividad R, Morgello S, et al. (2009). Expression of the translocator protein of 18 kDa by microglia,macrophages and astrocytes based on immunohistochemical localization inabnormal human brain. Neuropathology and Applied Neurobiology 35: 306-328.
37. Coughlin JM, Ishizuka K, Kano SI, Edwards JA, Seifuddin FT, Shimano MA, et al. (2013). Marked reduction of soluble superoxide dismutase-1 (SOD1) incerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 18:10-11.
38. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. (2016). In vivo markers of inflammatory response in recent-onset schizophrenia: acombined study using [11C]DPA-713 PET and analysis of CSF and plasma. TranslPsychiatry 6: e777.
39. Coyle P, Tran N, Fung JN, Summers BL, Rofe AM (2009). Maternal dietary zincsupplementation prevents aberrant behavior in an object recognition taskin mice offspring exposed to LPS in early pregnancy. Behav Brain Res 197:210-218.
40. Demontis D, Nyegaard M, Buttenschøn HN, Hedemand A, Pedersen CB, Grove Jet al (2011). Association of GRIN1 and GRIN2A-D with schizophrenia and geneticinteraction with maternal herpes simplex virus-2 infection affecting disease risk. Am J Med Genet B Neuropsychiatr Genet 156B: 913-922.
41. Dickerson F, Stallings C, Origoni A, Schroeder J, Khushalani S, Yolken R (2014). Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull 40:796-803.
42. Dimitrov DH (2011). Correlation or coincidence between monocytosis andworsening of psychosis symptoms in veterans with schizophrenia SchizophrRes 126: 306-307.
43. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M (2009). Redoxdysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19:220-230.
44. Doorduin J, de Vries EFJ, Willemsen ATM, de Groot JC, Dierckx RA, Klein HC(2009). Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50: 1801-1807.
45. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, Cohen D,Versnel MA, et al. (2010). Inflammatory gene expression in monocytesof patients with schizophrenia: overlap and difference with bipolar disorder. Astudy in naturalistically treated patients. Int J Neuropsychopharmacol 13:1369-1381.
46. Eaton W, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, et al. (2006). Association ofschizophrenia and autoimmune diseases: linkage of Danish national registers. AmJ Psychiatry 163: 521-528.
47. Eaton W, Pederson M, Nielsen P, Mortensen P (2010). Autoimmune diseases,bipolar disorder, and non-affective psychosis. Bipolar Disord 12: 638-646.
48. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2010). Inflammation-induced anhedonia: endotoxin reduces ventral striatum responsesto reward. Biol Psychiatry 68: 748-754.
49. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients withschizophrenia. Neurosci Lett 313: 96-98.
50. Ezeoke A, Mellor A, Buckley P, Miller BJ (2013). A systematic quantitative reviewof blood autoantibody elevations in schizophrenia. Schizophrenia Res 150:245-251.
51. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. (2007). Effectsof interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokineinduceddepression. Biol Psychiatry 62: 1324-1333.
52. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, et al. (2015). Inflammation isassociated with decreased functional connectivity within corticostriatal rewardcitcuitry in depression. Mol Psychiatry 21: 1358-1365.
53. Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R (2007). Associations betweenChlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry 12:264-272.
54. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, et al. (2016). C-reactive protein is increased in schizophrenia but is not altered byantipsychotics: meta-analysis and implications. Mol Psychiatry 21: 554-564.
55. Flatow J, Buckley P, Miller B (2013). Meta-analysis of oxidative stress inschizophrenia. Biol Psychiatry 74: 400-409.
56. Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS (2015). Biology ofbone tissue: structure, function, and factors that influence bone cells. BioMed ResInt 2015: 421746.
57. Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, Lestage J, et al. (2007). Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within themouse extended amygdala, hippocampus and hypothalamus, that parallel theexpression of depressive-like behavior. Psychoneuroendocrinology 32: 516-531.
58. Fung SJ, Joshi D, Fillman SG, Weickert CS (2014). High white matter neuron densitywith elevated cortical cytokine expression in schizophrenia. Biol Psychiatry75: e5-e7.
59. Garay PA, Hsiao EY, Patterson PH, McAllister AK (2013). Maternal immuneactivation causes age-and region-specific changes in brain cytokines in offspringthroughout development. Brain Beahv Immun 31: 54-68.
60. Gao L, Li Z, Chang S, Wang J (2014). Association of interleukin-10 polymorphismswith schizophrenia: a meta-analysis. PLoS One 9: e90407.
61. Gardner RM, Dalman C, Wicks S, Lee BK, Karlsson H (2013). Neonatal levels ofacute phase proteins and later risk of non-affective psychosis. Transl Psychiatry19: e228.
62. Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA (2009). A uniquedual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 4: e4801.
63. Gaspar PA, Bustamante ML, Silva H, Aboitiz F (2009). Molecular mechanismsunderlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem 111: 891-900.
64. Gaughran F, O'Neill E, Sham P, Daly RJ, Shanahan F (2002). Soluble interleukin 2receptor levels in families of people with schizophrenia. Schizophr Res 56:235-239.
65. Gilvarry C, Sham P, Jones P, Cannon M, Wright P, Lewis SW, et al. (1996). Family history of autoimmune diseases in psychosis. Schizophr Res 19:33-40.
66. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. (2010). Fatemapping analysis reveals that adult microglia derive from primitive macrophages. Science 330: 841-845.
67. Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R, et al. (2013). Stress inpuberty unmasks latent neuropathological consequences of prenatal immuneactivation in mice. Science 339: 1095-1099.
68. Giovanoli S, Weber-Stadbauer U, Scvhedlowski M, Meyer U, Engler H (2016). Prenatal immune activation causes hippocampal synaptic deficits in the absenceof overt microglia anomalies. Brain Beahv Immun 55: 25-38.
69. Girard S, Tremblay L, Lepage M, Sebire G (2010). IL-1 receptor antagonist protectsagainst placental and neurodevelopmental defects induced by maternalinflammation. J Immunol 184: 3997-4005.
70. Goldsmith D, Rapaport MH, Miller BJ (2016). Meta-analysis of cytokine alterationsin psychiatric patients: comparisons between schizophrenia, bipolar disorder, anddepression. Mol Psychiatry In press.
71. Graham KL, Bodenheimer CM, Ezeoke A, Buckley PF, Miller BJ (2014). Urinary tractinfections in acute relapse of psychosis. JClin Psychiatry 75: 379-385.
72. Grüber L, Bunse T, Weidinger E, Reichard H, Müller N (2014). Adjunctive recombinanthuman interferon gamma-1b for treatment-resistant schizophrenia in2 patients. J Clin Psychiatry 75: 266-1267.
73. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. (2007). Impairedglutathione synthesis in schizophrenia: convergent genetic and functionalevidence. Proc Natl Acad Sci USA 104: 16621-16626.
74. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. (1999). Plasmalevels of cytokines and soluble cytokine receptors in psychiatric patients uponhospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res33: 407-418.
75. Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, et al. (2015). Agerelatedincreases in basal ganglia glutamate are associated with TNF, reducedmotivation and decreased psychomotor speed during IFN-alpha treatment:preliminary findings. Brain Behav Immun 46: 17-22.
76. Harrison NA, Voon V, Cercignani M, Cooper EA, Pessiglione M, Critchley HD (2015). A neurocomputational account of how inflammation enhances sensitivity topunishments versus rewards. Biol Psychiatry 80: 73-81.
77. Harvey L, Boksa P (2014). Additive effects of maternal iron deficiency and prenatalimmune activation on adult behaviors in rat offspring. Brain Behavior Immun 40:27-37.
78. Havlicek J, Gasova ZG, Smith AP, Zvara K, Flegr J (2001). Decrease of psychomotorperformance in subjects with latent 'asymptomatic' toxoplasmosis. Paristology122: 515-520.
79. Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, et al. (2014). Inflammatory molecular signature associated with infectious agents inpsychosis. Schizoprhenia Bulletin 40: 963-972.
80. Hoseth EZ, Westlye LT, Hope S, Dieset I, Aukrust P, Melle I, et al. (2016). Association between cytokine levels, verbal memory and hippocampusvolume in psychotic disorders and healthy controls. Acta Psychiatr Scand 133:53-62.
81. Hudson ZD, Miller BJ (2016). Meta-Analysis of cytokine and chemokine genes inschizophrenia. submitted to clinical schizophrenia, related psychoses. (In press).
82. Hutchison WM, Aitken PP, Wells BW (1980). Chronic Toxoplasma infections andmotor performance in the mouse. Ann Trop Med Parasitol 74: 507-510.
83. Ingman WV, Robertson SA (2009). The essential roles of TGFB1 in reproduction. Cytokine Growth Factor Rev 20: 233-239.
84. Jiang L, Lindpaintner K, Li H-F, Gu N-F, Langen H, He L, et al. (2003). Proteomicanalysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids25: 49-57.
85. Juckel G, Friedel E, Koslowski M, Witthaus H, Ozgurdal S, Gudlowski Y, et al. (2012). Ventral striatal activation during reward processing in subjects with ultra-high riskfor schizophrenia. Neuropsychobiology 66: 50-56.
86. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, et al. (2006). Dysfunction of ventral striatal reward prediction in schizophrenic patientstreated with typical, but not atypical, neuroleptics. Psychopharmacology 187:222-228.
87. Kalmady SV, Venkatasubramanian G, Shivakumar V, Gautham S, Subramaniam A,Jose DA, et al. (2014). Relationship between Interleukin-6 gene polymorphism andhippocampal volume in antipsychotic-naïve schizophrenia: evidence for differentialsusceptibility PLoS One 9: e96021.
88. Kano S, Nwulia E, Niwa M, Chen Y, Sawa A, Cascella N (2011). Altered MHC class Iexpression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neurosci Res 71: 289-293.
89. Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. (2015). D-serine for the treatment of negative symptoms in individuals atclinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled,randomized parallel group mechanistic proof-of-concept trial. Lancet Psychiatry2: 403-412.
90. Kegel ME, Bhat M, Skogh E, Samuelsson M, Lundberg K, Dahl ML, et al. (2014). Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res 7:15-22.
91. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remingston G, et al. (2015). Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivostudy with [18 F]-FEPPA. Schizophr Bull 41: 85-93.
92. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011). Physiology of microglia. Physiol Rev 91: 461-553.
93. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB (2014). Association ofserum interleukin 6 and C-reactive protein in childhood with depression andpsychosis in young adult life: a population-based longitudinal study. JAMAPsychiatry 71: 1121-1128.
94. Kirkpatrick B, Miller BJ (2013). Inflammation and schizophrenia. Schizophr Bull 39:1174-1179.
95. Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, et al. (2009). Effects of clozapine and olanzapine on cytokine systems are closely linked toweight gain and drug-induced fever. Psychoneuroendocrinology 34: 118-128.
96. Koola MM (2016). Methodological issues in cytokine measurement in schizophrenia. Indian J Psychol Med 38: 6-9.
97. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS (2001). Neuroleptics normalizeincreased release of interleukin-1 beta and tumor necrosis factor-alpha frommonocytes in schizophrenia. Schizophr Res. 50: 169-175.
98. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, et al. (2010). The association of infectious agents and schizophrenia. World J Biol Psychiatry11: 739-743.
99. Krause DL, Wagner JK, Wildenauer A, Matz J, Weidinger E, Riedel M, et al. (2012a). Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6. Eur Arch Psychiatry Clin Neurosci 262: 393-401.
100. Krause D, Wagner J, Matz J, Weidinger E, Obermeier M, Riedel M, et al. (2012b). Monocytic HLA DR antigens in schizophrenic patients. Neurosci Res 72: 87-93.
101. Kucharska-Mazur J, Tarnowski M, Dogowska B, Budkowska M, Pdziwiatr D,Jaboski M, et al. (2014). Novel evidence for enhanced stem cell trafficking inantipsychotic-naïve subjects during their first psychotic episode. J Psychiatr Res49: 18-24.
102. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010). Adjuvantaspirin therapy reduces symptoms of schizophrenia spectrum disorders: resultsfrom a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520-527.
103. Labad J, Stojanovic-Pérez A, Montalvo I, Solé M, Cabezas Á, Ortega L, et al. (2015). Stress biomarkers as predictors of transition to psychosis in at-risk mental states:roles for cortisol, prolactin and albumin. J Psychiatr Res 60: 163-169.
104. Labouesse MA, Langhans W, Meyer U (2015). Long-term pathological consequencesof prenatal infection: beyond brain disorders. Am J Physiol Regul IntegrComp Physiol 309: R1-R12.
105. Labouesse MA, Dong E, Grayson DR, Guidotti A, Meyer U (2015). Maternal immuneactivation induces GAD1 and GAD2 promoter remodeling in the offspringprefrontal cortex. Epigenetics 10: 1143-1155.
106. Lachance LR, McKenzie K (2014). Biomarkers of gluten sensitivity in patients withnon-affective psychosis: a meta-analysis. Schizophr Res 152: 521-527.
107. Laney D, Philip N, Miller BJ (2015). Recurrent urinary tract infections in acutepsychosis. Schizophr Res 164: 275-276.
108. Lanté F, Meunier J, Guiramand J, De Jesus Ferreira MC, Cambonie G, Aimar R, et al. (2008). Late N-acetylcysteine treatment prevents the deficits induced in theoffspring of dams exposed to an immune stress during gestation. Hippocampus18: 602-609.
109. Laskaris LE, Di Biase MA, Everall I, Chana G, Christopoulos A, Skafidas E, et al. (2016). Microglial activation and progressive brain changes in schizophrenia. Br J Pharmacol 173: 666-680.
110. Lee P, Peng H, Gelbart T, Wang L, Beutler E (2010). Regulation of hepcidintranscription by interleukin-1 and interleukin-6. Proc Natl Acad Sci 102:1906-1910.
111. Lenczowski MJ, Bluthe RM, Roth J, Rees GS, Rushforth DA, van Dam AM, et al. (1999). Central administration of rat IL-6 induces HPA activation and fever but notsickness behavioral in rats. Am J Physiol 276: R652-R658.
112. Levine J, Gutman J, Feraro R, Levy P, Kimhi R, Leykin I, et al. (1997). Side effectprofile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology 36: 172-176.
113. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H, et al. (2010). Tyrosine hydroxylase,interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheralblood mononuclear cells from schizophrenia patients as determined by semiquantitativeanalysis. Psychiatry Res 176: 1-7.
114. Löffler S, Löffler-Ensgraber M, Fehsel K, Klimke A (2010a). Clozapine therapy raisesserum concentrations of high sensitive C-reactive protein in schizophrenicpatients. Int Clin Psychopharmacol 25: 101-106.
115. Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K (2010b). Clozapinemobilizes CD34+ hematopoietic stem and progenitor cells and increases plasmaconcentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol30: 591-595.
116. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997). In vivoimmunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221-225.
117. Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F (2016). Antioxidanttreatments for schizophrenia. Cochrane Database Syst Rev 2: CD008919.
118. Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL, Miller AH (2008). IFN-alphainduced motor slowing is associated with increased depression and fatigue inpatients with chronic hepatitis C. Brain Behav Immun 22: 870-880.
119. Manu P, Correll CU, Wampers M, Mitchell AJ, Probst M, Vancampfort D, et al. (2014). Markers of inflammation in schizophrenia: association vs. causation. WorldPsychiatry 13: 189-192.
120. Marshall SA, McClain JA, Kelso ML, Hopkins DM, Pauly JR, Nixon K (2013). Microglialactivation is not equivalent to neuroinflammation in alcohol-induced neurodegeneration:the importance of microglia phenotype. Neurobiol Dis 54: 239-251.
121. Martin LF, Kem WR, Freedman R (2004). Alpha-7 nicotinic receptor agonists:potential new candidates for the treatment of schizophrenia. Psychopharmacology(Berl) 174: 54-64.
122. Martínez-Gras I, Garciá-Sánchez F, Guaza C, Rodríguez-Jiménez R, Andrés-Esteban E,Palomo T, et al. (2012). Altered immune function in unaffected first-degree biologicalrelatives of schizophrenia patients. Psychiatry Res 200: 1022-1025.
123. Massi P, Vaccani A, Parolaro D (2006). Cannabinoids, immune system and cytokinenetwork. Curr Pharm Des 12: 3135-3146.
124. Matcovitch-Natan O, Winter DR, Giladi A, Aguilar SV, Spinrad A, Sarrazin S, et al. (2016). Microglia development follows a stepwise program to regulate brainhomeostasis. Science 353: aad8670.
125. Mayilyan KR, Weinberger DR, Sim RB (2008). The complement system inschizophrenia. Drug News Perspect 21: 200-210.
126. McAdams C, Leonard BE (1993). Neutrophil and monocyte phagocytosis indepressed patients. Prog Neuropsychopharmacol Biol Psychiatry 17: 971-984.
127. Meyer U (2013). Developmental neuroinflammation and schizophrenia. Progress inNeuro-Psychopharmacology &. Biological Psychiatry 42: 20-34.
128. Meyer U (2014). Prenatal poly(i:C) exposure and other developmental immuneactivation models in rodent systems. Biol Psychiatry 75: 307-315.
129. Miller B, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). Meta-analysis ofcytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 70: 663-671.
130. Miller BJ, Graham KL, Bodenheimer CM, Culpepper NH, Waller JL, Buckley PF(2013). A prevalence study of urinary tract infections in acute relapse ofschizophrenia. J Clin Psychiatry 73: 271-277.
131. Miller BJ, Bodenheimer CM, Culpepper NH, Graham KL, Buckley PF (2013). Differential white blood cell counts may predict urinary tract infection in acute nonaffectivepsychosis. Schizophr Res 147: 400-401.
132. Miller B, Culpepper N, Rapaport M, Buckley P (2013). Prenatal inflammation andneurodevelopment in schizophrenia: a review of human studies. Prog Neuro-Psychopharmacol Biol Psychiatry 42: 92-100.
133. Miller B, Gassama B, Sebastian D, Buckley P, Mellor A (2013). Meta-analysis oflymphocytes in schizophrenia: clinical status and antipsychotic effects. BiolPsychiatry 73: 993-999.
134. Miller B, Mellor A, Buckley P (2013). Total and differential white blood cell counts,high-sensitivity c-reactive protein, and the metabolic syndrome in non-affectivepsychoses. Brain Behavior Immun 31: 82-89.
135. Miller BJ, Culpepper N, Rapaport MH (2014). C-Reactive Protein inSchizophrenia: A Review and Meta-Analysis. Clin Schizophr Relat Psychoses 7:223-230.
136. Miller BJ, Timonen M, Isohanni M (2014). Cytokine abnormalities, inflammation andpsychosis in the northern finland 1966 birth cohort. Eur Psychiatry 29: S519.
137. Miller BJ, Dias JK, Lemos HP, Buckley PF (2016). An Open-Label, Pilot Trial ofAdjunctive Tocilizumab in Schizophrenia. J Clin Psychiatry 77: 275-276.
138. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul Net al (2011). Stress and inflammation reduce brain-derived neurotrophic factorexpression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 72: 1677-1684.
139. Monji A, Kato T, Kanba S (2009). Cytokines and schizophrenia: microglia hypothesisof schizophrenia. Psychiatry Clin Neurosci 63: 257-265.
140. Monroe JM, Buckley PF, Miller BJ (2015). Meta-analysis of anti-toxoplasma gondiiigm antibodies in acute psychosis. Schizophr Bull 41: 989-998.
141. Monteleone P, Fabrazzo M, Tortorella A, Maj M (1997). Plasma levels of inteleukin-6and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapinetreatment. Psychiatry Res 71: 11-17.
142. Muller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, et al. (2004). COX-2 inhibition as a treatment approach in schizophrenia: immunologicalconsiderations and clinical effects of celecoxib add-on therapy. Eur ArchPsychiatry Clin Neurosci 254: 14-22.
143. Müller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, et al. (2012). Impaired monocyte activation in schizophrenia. Psychiatry Res 198:341-346.
144. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013). Neuroinflammation andpsychiatric illness. J Neuroinflammation 10: 43.
145. Najjar S, Pearlman DM (2015). Neuroinflammation and white matter pathology inschizophrenia: systematic review. Schizophr Res 161: 102-112.
146. Narendran R, Frankle WG (2016). Comment on Analyses and Conclusions of"Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an[11C]PBR28 PET brain imaging study". Am J Psychiatry 173: 536-537.
147. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the ironregulatory hormone hepcidin. J Clin Invest 113: 1271-1276.
148. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, et al. (2012). Alterationsof the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry 71: 898-905.
149. Nielsen PR, Meyer U, Mortensen PB (2016). Individual and combined effectsof maternal anemia and prenatal infection on risk for schizophrenia in offspring. Scz Res 172: 35-40.
150. Nielsen PR, Agerbo E, Skogstrand K, Hougaard DM, Meyer U, Mortensen PB(2015). Neonatal levels of inflammatory markers and later risk of schizophrenia. Biol Psychiatry 77: 548-555.
151. Nielsen PR, Benros ME, Mortensen PB (2014). Hospital contacts with infection andrisk of schizophrenia: a population-based cohort study with linkage of Danishnational registers. Schizophr Bull 40: 1526-1532.
152. Nikkilä HV, Müller K, Ahokas A, Miettinen K, Rimón R, Andersson LC (1999). Accumulation of macrophages in the CSF of schizophrenic patients. Am JPsychiatry 156: 1725-1729.
153. Nikkilä HV, Müller K, Ahokas A, Rimón R, Andersson LC (2001). Increased frequencyof activated lymphocytes in the cerebrospinal fluid of patients with acuteschizophrenia. Schizophr Res 49: 99-105.
154. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, et al. (2005). Elevated levels of kynurenic acid in the cerebrospinal fluid of male patientswith schizophrenia. Schizophr Res 80: 315-322.
155. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, et al. (2013). Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia:a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39:1230-1241.
156. Nimmerjahn A, Kirchhoff F, Helmchen F (2005). Resting microglial cellsare highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318.
157. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN (2006). Anautoimmune or an inflammatory process in patients with schizophrenia, schizoaffectivedisorder, and in their biological relatives. Schizophr Res 84: 180-182.
158. O'Connell KE, Thakore J, Dev KK (2014). Pro-inflammatory cytokine levels are raisedin female schizophrenia patients treated with clozapine. Schizophr Res 156: 1-8.
159. O'Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, et al. (2009). To assess, to control, to exclude: effects of biobehavioral factors on circulatinginflammatory markers. Brain Behav Immun 23: 887-897.
160. Paintlia MK, Paintlia AS, Contreras MA, Singh I, Singh AK (2008). Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matterinjury: attenuation by N-acetylcysteine. Exp Neurol 210: 560-576.
161. Park MH, Kwon YJ, Jeong HY, Lee HY, Hwangbo Y, Yoon HJ, et al. (2012). Association between Intracellular Infectious Agents and Schizophrenia. ClinPsychopharmacol Neurosci 10: 117-123.
162. Pearce BD, Hubbard S, Rivera HN, Wilkins PP, Fisch MC, Hopkins MH, et al. (2013). Toxoplasma gondii exposure affects neural processing speed asmeasured by acoustic startle latency in schizophrenia and controls. Scz Res 150:258-261.
163. Pearlman DM, Najjar S (2014). Meta-analysis of the association between N-methyld-aspartate receptor antibodies and schizophrenia, schizoaffectivedisorder, bipolar disorder, and major depressive disorder. Schizophr Res 157:249-258.
164. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TDet al (2015). Towards a psychosis risk blood diagnostic for persons experiencinghigh-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull41: 419-428.
165. Pershing ML, Bortz DM, Pocivavsek A, Fredericks PJ, Jorgensen CV, Vunck SA, et al. (2015). Elevated levels of kynurenic acid during gestation produce neurochemical,morphological, and cognitive deficits in adulthood: Implications for schizophrenia. Neuropharmacology 90: 33-41.
166. Pletnikov MV, Rubin SA, Schwartz GJ, Carbone KM, Moran TH (2000). Effects ofneonatal rat Borna disease virus (BDV) infection on the postnatal development ofthe brain monoaminergic systems. Brain Res Dev Brain Res 119: 179-185.
167. Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R (2012). Pre-and post-natalexposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 35:1605-1612.
168. Pollmächer T, Hinze-Selch D, Mullington J (1996). Effects of clozapine on plasmacytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 6:403-409.
169. Qin H, Zhang L, Xu G, Pan X (2013). Lack of association between TNF rs1800629polymorphisms and schizophrenia risk: a meta-analysis. Psychiatry Research209: 314-319.
170. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, et al. (2010). Chronic interferon-alpha administration disrupts sleep continuity and depth inpatients with hepatitis C: association with fatigue, motor slowing, and increasedevening cortisol. Biol Psychiatry 68: 942-949.
171. Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M (2015). Mitochondrialdysfunction in schizophrenia: pathways, mechanisms and implications. NeurosciBiobehav Rev 48: 10-21.
172. Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA (2000). Tryptophanand tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 48:231-238.
173. Reús G, Fries G, Stertz L, Badawy M, Passos I, Barichello T, et al. (2015). The role ofinflammation and microglial activation in the pathophysiology of psychiatricdisorders. Neuroscience 300: 141-154.
174. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J (2012). Immunomodulatoryeffects of clozapine and their clinical implications: what have we learned so far. Schizophr Res 140: 204-213.
175. Rwegellera GG, Fernando KA, Okong'o O (1982). Bactericidal activity of neutrophilsof schizophrenic patients. Med J Zambia 16: 21-22.
176. Saha S, Chant D, McGrath J (2007). A systematic review of mortality inschizophrenia: is the differential mortality gap worsening over time Arch GenPsychiatry 64: 1123-1131.
177. Salamone JD, Cousins MS, Bucher S (1994). Anhedonia or anergia Effects of haloperidoland nucleus accumbens dopamine depletion on instrumental responseselection in a T-maze cost/benefit procedure. Behav Brain Res 65: 221-229.
178. Salamone JD, Correa M (2012). The mysterious motivational functions of mesolimbicdopamine. Neuron 76: 470-485.
179. Santos Sória Ld, Moura Gubert Cd, Ceresér KM, Gama CS, Kapczinski F (2012). Increased serum levels of C3 and C4 in patients with schizophrenia compared toeutymic patients with bipolar disorder and healthy. Rev Bras Psiquiatr 34: 119-120.
180. Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A,McMahon RP, et al. (2011). Impaired kynurenine pathway metabolism in theprefrontal cortex of individuals with schizophrenia. Schizophr Bull. 37: 1147-1156.
181. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421-427SI.
182. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, et al. (2005). Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenicpatients on stable antipsychotic medication. Neuropsychiatr Dis Treat1: 171-177.
183. Schmitt A, Hasan A, Gruber O, Falkai P (2011). Schizophrenia as a disorder ofdisconnectivity. Eur. Arch. Psychiatry Clin. Neurosci 261: S150-S154.
184. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530.
185. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. (2015). Increased levels of IL-6 in the cerebrospinal fluid of patients with chronicschizophrenia-significance for activation of the kynurenine pathway. J PsychiatryNeurosci. 2: 126-133.
186. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature 530: 177-183.
187. Severance EG, Gressitt KL, Halling M, Stallings CR, Origoni AE, Vaughan C, et al. (2012). Complement C1q formation of immune complexes with milk caseins andwheat glutens in schizophrenia. Neurobiol Dis 48: 447-453.
188. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. (2009). Commonvariants on chromosome 6p22. 1 are associated with schizophrenia. Nature 460:753-757.
189. SIRS Symposium. Potential role of NMDA-receptor antibodies in schizophrenia:overlap and distinction from NMDA receptor encephalitis. Symposium presentation,4th Schizophrenia International Research Society Conference; Florence,Italy. April 8, 2014.
190. Shibuya M, Watanabe Y, Nunokawa A, Egawa J, Kaneko N, Igeta H, et al. (2014). Interleukin 1 beta gene and risk of schizophrenia: detailed case-control andfamily-based studies and an updated meta-analysis. Hum Psychopharmacol 29:31-37.
191. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007). Maternal immuneactivation alters fetal brain development through interleukin-6. J Neurosci 27:10695-10702.
192. Solbrig MV, Koob GF, Fallon JH, Reid S, Lipkin WI (1996). Prefrontal cortex dysfunctionin Borna disease virus (BDV)-infected rats. Biol Psychiatry 40: 629-636.
193. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS(2014). Efficacy of anti-inflammatory agents to improve symptoms in patients withschizophrenia: an update. Schizophr Bull 40: 181-191.
194. Srikanth S, Ravi V, Poornima KS, Shetty KT, Gangadhar BN, Janakiramaiah N(1994). Viral antibodies in recent onset, nonorganic psychoses: correspondencewith symptomatic severity. Biol Psychiatry 36: 517-521.
195. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, et al. (2006). Distribution of HLA-DR-positive microglia in schizophrenia reflects impairedcerebral lateralization. Acta Neuropathol 112: 305-316.
196. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. (2008). Immunological aspects in the neurobiology of suicide: elevated microglial densityin schizophrenia and depression is associated with suicide. J Psychiatr Res 42:151-157.
197. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, et al. (2014). Increased serum interleukin-6 levels in early stages of psychosis: associationswith at-risk mental states and the severity of psychotic symptoms. Psychneuroendocrinology41: 23-32.
198. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R, et al. (2010). Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PETstudy with [11C]DAA1106. Int J Neuropsychopharmacol 13: 943-950.
199. Torrey EF, Bartko JJ, Lun ZR, Yolken RH (2007). Antibodies to Toxoplasma gondii inpatients with schizophrenia: a meta-analysis. Schizophr Bull 33: 729-736.
200. Upthegrove R, Manzanares-Teson N, Barnes NM (2014). Cytokine function inmedication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155: 101-108.
201. Vallee BL, Falchuk KH (1993). The biochemical basis of zinc pathophysiology. Physiol Rev 73: 79-118.
202. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers Eet al (2008). Microglia activation in recent-onset schizophrenia: a quantitative(R)-[11C]PK11195 Positron Emission Tomography Study. Biol Psychiatry 64:820-822.
203. Vichaya EG, Hunt SC, Danzer R (2014). Lipopolysaccharide reduces incentivemotivation while boosting preference for high reward in mice. Neuropsychopharmacology39: 2884-2890.
204. Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA. (2015). Molecular mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 172: 1112-1121.
205. Volpe GE, Ward H, Mwamburi M, Dinh D, Bhalchandra S, Wanke C, et al. (2014). Associations of cocaine use and HIV infection with the intestinalmicrobiota, microbial translocation, and inflammation. J Stud Alcohol Drugs 75: 347-357.
206. Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, Meyer U(2016). Transgenerational transmission and modification of pathological traitsinduced by prenatal immune activation. Molecular Psychiatry advanced onlinepublication.
207. Wang AK, Miller BJ (2016). Meta-analysis of cerebrospinal fluid cytokine andtryptophan catabolite alterations in psychiatric patients: comparisons betweenschizophrenia, bipolar disorder, and depression. In preparation.
208. Webster JP, McConkey GA (2010). Toxoplasma gondii-altered host behavior: cluesas to mechanism of action. Folia Parisitol 57: 95-104.
209. Witting PA (1979). Learning capacity and memory of normal and Toxoplasmainfectedlaboratory rats and mice. Z Parasitenkd 61: 29-51.
210. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, et al. (2011). Downregulated kynurenine 3-monooxygenase gene expression andenzyme activity in schizophrenia and genetic association with schizophreniaendophenotypes. Arch Gen Psychiatry 68: 665-674.
211. Wonodi I, McMahon RP, Krishna N, Mitchell BD, Liu J, Glassman M, et al. (2014). Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism oncognitive function in schizophrenia. Schizophr Res 160: 80-87.
212. Xu M, He L (2010). Convergent evidence shows a positive association ofinterleukin-1 gene complex locus with susceptibility to schizophrenia in thecaucasian population. Schizophr Res 120: 131-142.
213. Yang L, Li FF, Han YC, Jia B, Ding Y (2015). Cannabinoid receptor CB2 is involved intetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide inMG-63 cells. Mediators Inflamm 2015: 362126.
214. Yao JK, Keshavan MS (2011). Antioxidants, redox signaling, and pathophysiologyin schizophrenia: an integrative view. Antioxid Redox Signal 15: 2011-2035.
215. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. (1994). Cytokine-specific central monoamine alterations induced by interleukin-1,-2 and-6. Brain Res 643: 40-49.
216. Zalcman S, Savina I, Wise RA (1999). Interleukin-6 increases sensitivity to thelocomotor-stimulating effects of amphetamine in rats. Brain Res 847: 276-283.
217. Zeni-Graiff M, Rizzo LB, Mansur RB, Maurya PK, Sethi S, Cunha GR, et al. (2016). Peripheral immuno-inflammatory abnormalities in ultra-high risk of developingpsychosis. Schizophr Res 176: 191-195.